Multiple System Atrophy Market to Register Immense Growth at a CAGR of 4% by 2032 | DelveInsight

With the expected launch of emerging therapies, the multiple system atrophy market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of MSA has amplified drug research and development. 

LAS VEGAS, Oct. 17, 2022 /PRNewswire/ -- DelveInsight's Multiple System Atrophy Market Insights report includes a comprehensive understanding of current treatment practices, multiple system atrophy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Multiple System Atrophy Market Report

• As per DelveInsight analysis, the multiple system atrophy market size in the 7MM was approximately USD 125 million in 2021.
• According to the assessment done by DelveInsight, the estimated total multiple system atrophy diagnosed prevalent cases in the 7MM were approximately 36K in 2021. 
• Globally, leading multiple system atrophy companies such as Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others are developing novel MSA drugs that can be available in the multiple system atrophy market in the coming years.
• The promising multiple system atrophy therapies in the pipeline include Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, and others.
• The growing diagnosed population of multiple system atrophy (MSA) and upcoming therapies in the 7MM are driving the multiple system atrophy market growth.

Discover which therapies are expected to grab the major multiple system atrophy market share @Multiple System Atrophy Market Report

Multiple System Atrophy Overview

Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.

The slowness of movement, tremors, rigidity, and incoordination are the first signs and multiple system atrophy symptoms. The parkinsonian type (MSA-P) with primary symptoms similar to Parkinson's disease and the cerebellar type (MSA-C) with primary symptoms featuring ataxia are the most prominent multiple system atrophy symptoms of evaluation.

Multiple system atrophy diagnosis is difficult, especially in the early stages, because many of the symptoms are similar to Parkinson's disease. Autonomic testing (such as blood pressure control and heart rate control), assessment of bladder function, and neuroimaging such as an MRI (magnetic resonance imaging) or PET scan are examples of diagnostic tests.

Multiple System Atrophy Epidemiology Segmentation

DelveInsight estimates that there were approximately 36K diagnosed prevalent cases of multiple system atrophy in the 7MM in 2021.

Among the EU5 countries, Germany had the highest number of multiple system atrophy diagnosed prevalent cases in 2021.

The multiple system atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Diagnosed Prevalent Cases of MSA
• Gender-specific DiagnosedPrevalent Cases of MSA
• Age-specific Diagnosed Prevalent Cases of MSA
• Type-specific Diagnosed Prevalent Cases of MSA

Download the report to understand which factors are driving multiple system atrophy epidemiology trends @Multiple System Atrophy Epidemiological Insights

Multiple System Atrophy Treatment Market 

The approved multiple system atrophy market segment includes NORTHERA (droxidopa), the world's first approved therapy for symptomatic nOH. Dainippon Sumitomo Pharma (DSP) developed it and commercialized it in Japan in 1989. DSP sold the drug license to Chelsea Therapeutics International in 2006. Chelsea received accelerated approval for NORTHERA from the US FDA in February 2014 for symptomatic benefit in adult patients with nOH, and exclusivity will expire in February 2021. nOH is found in approximately 66-90% of MSA patients and is a major cause of disability and injury in the disease.

There is currently no approved disease-modifying agent. The drug used to treat Parkinson's disease, most notably levodopa (SINEMET), is also prescribed for MSA patients. The efficacy of such medications, however, varies greatly among affected individuals. Other drugs used to treat Parkinson's disease and levodopa may be used to treat MSA patients. These include dopamine agonists like ropinirole (Requip) and pramipexole (Mirapexin), which increase dopamine receptor activity in the brain.

Moreover, the multiple system atrophy treatment market majorly covers off-label and generic treatments. Clonazepam, vitamin E, propanolol, baclofen, or amantadine have proven to be more effective. However, buspirone (off-label) improved upper-limb ataxia.

Depending on the severity of the other symptoms, drugs such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) may be used to treat urinary and erectile dysfunction symptoms, which are common in men with MSA.

To know more about multiple system atrophy treatment options, visit @MSA Treatment Drugs 

Multiple System Atrophy Pipeline Therapies and Key Companies

• Lu AF82422: H Lundbeck A/S
• Ampreloxetine (TD-9855): Theravance Biopharma
• AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc.
• ION464: Ionis Pharmaceuticals, Inc
• ATH434: Alterity Therapeutics

Learn more about the FDA-approved drugs for multiple system atrophy treatment @Drugs for MSA Treatment 

Multiple System Atrophy Market Dynamics

In recent years, there has been a greater understanding of the neuropathological aspects underlying MSA driving the multiple system atrophy market. Because of the numerous clinical features associated with MSA, tremendous effort is being made to develop reliable clinical criteria for diagnosis. The emerging pipeline has the potential for rapid development, and many therapies are in early and mid-stage trials, with approval changing the dynamics of the multiple system atrophy market.

Moreover, research studies with effective MoAs to treat MSA neuroprotective provide key pharma players with many exciting opportunities in the multiple system atrophy market. The anticipated approval of potential therapies may change and increase the multiple system atrophy market dynamics for the MSA treatment landscape. Furthermore, as the current diagnostic consensus criteria compete for a step forward, the definitive diagnosis of MSA is opportunistic.

However, the current consensus diagnostic criteria for MSA do not accurately define MSA, which impedes clinical trials of potential disease-modifying treatments in the multiple system atrophy market. The only pharmacologic treatment available is symptomatic, and the multiple system atrophy market lacks neuroprotective treatments.

Moreover, several pharmaceutical companies recently launched generic versions of Droxidopa (Northera) in 2021, saturating the current multiple system atrophy market. With the introduction of low-cost generics for Northera, the treatment sphere of MSA is expected to be hampered by the entry of more expensive emerging drugs.

Furthermore, the multiple system atrophy market cannot rely entirely on emerging therapies in the forecast period because the majority of ongoing trials are either in the early or mid-stage of development.

Scope of the Multiple System Atrophy Market Report

• Therapeutic Assessment: Multiple System Atrophy current marketed and emerging therapies
• Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Multiple System Atrophy Market Access and Reimbursement

Discover more about drugs for multiple system atrophy in development @Multiple System Atrophy Clinical Trials

Table of Contents

Related Reports

Multiple System Atrophy Epidemiology Forecast

Multiple System Atrophy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the multiple system atrophy epidemiology trends.

Multiple System Atrophy Pipeline

Multiple System Atrophy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key multiple system atrophy companies, including Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, among others.

Parkinson's Disease Market

Parkinson's Disease Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Parkinson's disease companies, including AbbVie, Teva Pharmaceuticals, Pharma Two B, Ipsen, Kyowa Kirin, among others.

Parkinson's Disease Pipeline

Parkinson's Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including AbbVie, Teva Pharmaceuticals, Pharma Two B, Ipsen, Kyowa Kirin, among others.

Parkinson's Disease Epidemiology

Parkinson's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Parkinson's disease epidemiology trends.

Other Trending Reports

Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market

Related Healthcare Blogs

Parkinsons's Disease Treatment Market

Parkinson's Disease Market Outlook

Parkinson's Disease: How close are we to a cure?

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP